UBS Group Upgrades Evommune (NYSE:EVMN) to Hold

Evommune (NYSE:EVMN) was upgraded by stock analysts at UBS Group to a “hold” rating in a research report issued to clients and investors on Sunday, Zacks reports.

Several other research analysts have also issued reports on the stock. Stifel Nicolaus set a $30.00 price target on shares of Evommune in a research note on Wednesday, September 9th. Raymond James Financial set a $18.00 target price on Evommune in a report on Wednesday, September 9th. Needham & Company LLC assumed coverage on Evommune in a research report on Wednesday, August 26th. They issued a “buy” rating and a $28.00 price target for the company. Weiss Ratings lowered shares of Evommune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 11th. Finally, Morgan Stanley lowered their price target on Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Evommune currently has an average rating of “Moderate Buy” and an average price target of $30.80.

Evommune Price Performance

Shares of NYSE:EVMN opened at $5.87 on Friday. The stock’s 50-day moving average is $10.93 and its 200 day moving average is $16.89. Evommune has a 1 year low of $5.85 and a 1 year high of $33.20. The company has a market cap of $212.85 million and a PE ratio of -0.53.

Evommune (NYSE:EVMN) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). Analysts expect that Evommune will post -3.29 EPS for the current fiscal year.

Institutional Trading of Evommune

Several institutional investors and hedge funds have recently modified their holdings of EVMN. Squarepoint Ops LLC purchased a new position in shares of Evommune in the second quarter valued at about $634,000. Velan Capital Investment Management LP boosted its stake in Evommune by 1.1% during the second quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock valued at $5,997,000 after buying an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Evommune during the 2nd quarter valued at approximately $340,000. Defilade Capital Management L.P. boosted its position in shares of Evommune by 215.0% during the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock valued at $15,601,000 after acquiring an additional 463,171 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new stake in Evommune in the first quarter worth $10,308,000.

Evommune Company Profile

Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.

Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.